Request Trial
istock-652532896_filograph
filograph / iStockphoto.com
16 October 2018Biotech

ERS Genomics signs CRISPR patent deal on industrial applications

ERS Genomics, the company providing access to CRISPR/Cas9 IP owned by Emmanuelle Charpentier, has signed a licensing deal with synthetic biology startup Syngulon.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotech
10x Genomics dealt major blow in sequencing fight
20 August 2026   Three disputed sequencing patents took the spotlight as the Federal Circuit weighed challenges to a trio of PTAB rulings.
Biotech
Europe’s missing biotech bridge: Why IP ownership matters more than capital access
17 August 2026   Europe’s biotechnology challenge is not only whether it can fund innovation. It is whether it can continue to originate and control the foundational IP positions from which future biotech value is created. Paul Calvo of Sterne Kessler explains.
Biotech
Masimo keeps $634m smartwatch award and moves to appeal
21 July 2026   Now a Danaher subsidiary, the company is contesting a number of orders after a California court finalised several aspects of the high-profile dispute.


Editor's picks

Abbott fends off Chinese rival’s patent challenge at UPC
MedTech
Abbott fends off Chinese rival’s patent challenge at UPC
18 August 2026

Editor's picks

MedTech
Abbott fends off Chinese rival’s patent challenge at UPC
18 August 2026

More features

10x Genomics dealt major blow in sequencing fight
SK Biopharmaceuticals settles epilepsy generic dispute
Vanda revives challenge over braille-free label on generic sleep disorder drug
Abbott fends off Chinese rival’s patent challenge at UPC
Former head of litigation at Nokia returns to Bird & Bird
Former USPTO acting director takes the helm at C4IP
Europe’s missing biotech bridge: Why IP ownership matters more than capital access
Novartis scores UK win in high-stakes Entresto fight